UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Blood, 2008-04, Vol.111 (8), p.4022-4028

2008

Link zum Volltext

Verfügbarkeit prüfen

Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

Clinical cancer research, 2009-01, Vol.15 (2), p.460-467

2009

Link zum Volltext

Verfügbarkeit prüfen

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Journal of clinical oncology, 2003-07, Vol.21 (14), p.2651-2657

2003

Link zum Volltext

Verfügbarkeit prüfen

Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Cancer research (Chicago, Ill.), 2011-07, Vol.71 (13), p.4696-4706

2011

Link zum Volltext

Verfügbarkeit prüfen

Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes

Clinical cancer research, 2009-06, Vol.15 (11), p.3705-3715

2009

Link zum Volltext

Verfügbarkeit prüfen

Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA

Clinical cancer research, 2013-09, Vol.19 (17), p.4854-4867

2013

Link zum Volltext

Verfügbarkeit prüfen

ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (13), p.5368-5378

2010

Link zum Volltext

Verfügbarkeit prüfen

Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

Clinical cancer research, 2007-06, Vol.13 (12), p.3552-3558

2007

Link zum Volltext

Verfügbarkeit prüfen

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Blood, 2001-09, Vol.98 (5), p.1326-1331

2001

Link zum Volltext

Verfügbarkeit prüfen

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

Blood, 2000-02, Vol.95 (3), p.999-1006

2000

Link zum Volltext

Verfügbarkeit prüfen

Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment

Clinical cancer research, 2013-06, Vol.19 (11), p.2962-2972

2013

Link zum Volltext

Verfügbarkeit prüfen

FMS-Like Tyrosine Kinase 3―Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

Cancer research (Chicago, Ill.), 2009-04, Vol.69 (7), p.3032-3041

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

Blood, 2004-05, Vol.103 (10), p.3644-3654

2004

Link zum Volltext

Verfügbarkeit prüfen

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

Blood, 2003, Vol.101 (1), p.278-285

2003

Link zum Volltext

Verfügbarkeit prüfen

FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (19), p.5014-5024

2012

Link zum Volltext

Verfügbarkeit prüfen

Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells

Cancer research (Chicago, Ill.), 2002-04, Vol.62 (8), p.2244-2247

2002

Link zum Volltext

Verfügbarkeit prüfen

GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment

Cancer research (Chicago, Ill.), 2008-07, Vol.68 (13), p.5414-5422

2008

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors

Cancer research (Chicago, Ill.), 2003-10, Vol.63 (19), p.6395-6404

2003

Link zum Volltext

Verfügbarkeit prüfen

Antifungal Therapy with Itraconazole Impairs the Anti-Lymphoma Effects of Rituximab by Inhibiting Recruitment of CD20 to Cell Surface Lipid Rafts

Cancer research (Chicago, Ill.), 2010-06, Vol.70 (11), p.4292-4296

2010

Link zum Volltext

Verfügbarkeit prüfen

Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides

Blood, 2002-02, Vol.99 (4), p.1320-1326

2002

Link zum Volltext

Verfügbarkeit prüfen

The immunogenicity of Bcr-Abl-expressing dendritic cells is dependent on the Bcr-Ab1 kinase activity and dominated by Bcr-Abl-regulated antigens

Blood, 2007, Vol.110 (7), p.2556-2560

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects

Clinical cancer research, 1996-07, Vol.2 (7), p.1115-1122

1996

Link zum Volltext

Verfügbarkeit prüfen

Interleukins : clinical pharmacology and therapeutic use

Drugs (New York, N.Y.), 1994-11, Vol.48 (5), p.667-677

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

KollektionPublisher website

ThemaAntineoplastic Agents

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(24)
Pharmacology. Drug Treatments
(23)
Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Oncology
(15)
Female
(13)
Hematologic And Hematopoietic Diseases
(11)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(11)
Male
(11)
Middle Aged
(11)
Aged
(10)
Animals
(10)
Adult
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Mice
(8)
Tumors
(8)
Immunotherapy
(7)

13 weitere anzeigen...

Weniger anzeigen...

Kollektion

Publisher or Other Site
(24)
MEDLINE
(23)
EZB Electronic Journals Library
(23)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(2)
IngentaConnect Journals
(1)
Ingenta
(1)
Springer Journals
(1)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use

Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes

Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA

ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment

FMS-Like Tyrosine Kinase 3―Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy

Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells

GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors

Antifungal Therapy with Itraconazole Impairs the Anti-Lymphoma Effects of Rituximab by Inhibiting Recruitment of CD20 to Cell Surface Lipid Rafts

Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides

The immunogenicity of Bcr-Abl-expressing dendritic cells is dependent on the Bcr-Ab1 kinase activity and dominated by Bcr-Abl-regulated antigens

Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects

Interleukins : clinical pharmacology and therapeutic use

Aktive Filter

Suchergebnisse filtern